Hostname: page-component-8448b6f56d-wq2xx Total loading time: 0 Render date: 2024-04-24T21:39:39.037Z Has data issue: false hasContentIssue false

U-47700: The new emerging opioid drug

Published online by Cambridge University Press:  23 March 2020

M. De Dios Felis
Affiliation:
Institut de Neuropsiquiatria i Adiccions, Psychiatry, Barcelona, Spain
E. Monteagudo Gimeno
Affiliation:
Institut de Neuropsiquiatria i Adiccions, Psychiatry, Barcelona, Spain
S. Pérez Gonzaléz
Affiliation:
Institut de Neuropsiquiatria i Adiccions, Psychiatry, Barcelona, Spain
A. Trabsa Biskri
Affiliation:
Institut de Neuropsiquiatria i Adiccions, Psychiatry, Barcelona, Spain
L. Galindo Guarin
Affiliation:
Institut de Neuropsiquiatria i Adiccions, Psychiatry, Barcelona, Spain
M. Grifell Guardia
Affiliation:
Institut de Neuropsiquiatria i Adiccions, Psychiatry, Barcelona, Spain
P. Quintana Mathe
Affiliation:
Institut de Neuropsiquiatria i Adiccions, Psychiatry, Barcelona, Spain
M. Torrens Melich
Affiliation:
Institut de Neuropsiquiatria i Adiccions, Psychiatry, Barcelona, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The trans-3;4-dichloro-N-(2-(dimethylamine) cyclohexyl) labelled as U-47700 has a high affinity with the selective receptor, considered to have 7.5 times the binding affinity of morphine; as a result, it is sold as a recreational drug because of its analgesic and euphoric effects. Several toxicity cases and some fatalities have been reported during 2016.

Objectives

To describe the presence of trans-3;4-dichloro-N-(2-(dimethylamine) cyclohexyl) in samples delivered to Energy Control during 2016 in Barcelona.

Methods

From January 2016 to October 2016, 4031 samples were delivered and only those samples containing trans-3;4-dichloro-N-(2-(dimethylamine) cyclohexyl) were studied, 6 of them were analysed as U-47700 (0.148%). Samples were analysed by energy control, a Spanish harm-reduction NGO that offers users the possibility of analysing the substances they intend to consume. Analysis was done by gas chromatography–mass spectrometry.

Results

From the 6 samples that were analysed as trans-3;4-dichloro-N-(2-(dimethylamine) cyclohexyl), the presentation of 4 of them was white powder and the rest were not described. The procedence of the samples was Canada (2), USA (1), Sweden (1), Holland (1) and the remaining sample was not described. All samples were received during 2016.

Conclusions

The use of trans-3;4-dichloro-N-(2-(dimethylamine)cyclohexyl) is progressively increasing in Barcelona. Its harmful effects are being reported in recent medical literature and consumption represents an emerging issue, gaining popularity among recreational opioid users. It is potentially lethal when mixed with depressants like alcohol or benzodiazepines and overdose risk is higher compared to other opioids. This drug is not being detected by routine in medical test.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster Walk: Substance related and addictive disorders – Part 2
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.